p53 Autoantibodies in Patients with Primary Ovarian Cancer Are Associated with Higher Age, Advanced Stage and a Higher Proportion of p53-Positive Tumor Cells

Vogl, Florian D.; Stickeler, Elmar; Weyermann, Maria; Köhler, Tanja; Grill, H. J.; Negri, Gian Luca; Kreienberg, R.; Runnebaum, I. B.

doi:10.1159/000012069

Cited by 21 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports from Vogl and colleagues [23] revealed 46% prevalence of circulating p53 autoantibodies in a study population comprising 83 OVCA patients. Their study also indicated that in a bivariate analysis, patients with anti-p53 autoantibodies had a 1.96-fold risk for relapse (95% confidence interval 1.02–3.78).…”

Section: Discussionmentioning

confidence: 99%

Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence

Chatterjee

Dyson

Levin

et al. 2012

CBM

View full text Add to dashboard Cite

Ovarian cancer (OVCA) has a high incidence of recurrence and a high rate of mortality. We performed a pilot study to evaluate the usefulness of tumor autoantibodies to tumor associated antigens (TAA) to predict OVCA recurrence. A validation study with 56 antigens, previously identified in the initial phase of the study, along with 13 known tumor antigens on protein arrays was performed on an independent cohort of recurrent and non-recurrent OVCA patients. Statistical analyses revealed that a panel of 3 antigens predicted recurrence at a median time of 9.07 months prior to clinical recurrence in a study population, where majority of patients had CA125 values less than 35 U/ml, with an average sensitivity, specificity and accuracy of 94.7%, 86.7% and 93.3% respectively. One of the top 3 antigens has been associated with the development of polymyositis (PM) which has been shown in some cases to precede the occurrence of ovarian carcinoma. Our results indicate that these 3 antigens have potential for predicting recurrence at an early time and may have better prognostic utility than CA125 alone for early therapeutic intervention. These biomarkers could guide us to identify those patients that could benefit most from maintenance or consolidation therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence

Chatterjee

Dyson

Levin

et al. 2012

CBM

View full text Add to dashboard Cite

show abstract

“…30 OVCA cells express mutated forms of p53 [31][32][33] and/or BRCA-1 34,35 tumor suppressor genes. Ovarian tumor cells also express high levels of the CA-125 [36][37][38] and MUC1 39 TAA.…”

Section: Discussionmentioning

confidence: 99%

Induction of cytotoxic T lymphocytes against ovarian cancer‐initiating cells

Weng

Song

Durfee

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

The majority of patients with stage III/IV ovarian carcinoma that respond initially to standard therapies ultimately undergo relapse due to the survival of small populations of cells with tumor-initiating potential. These ovarian cancer (OVCA)-initiating cells (OCIC) are sometimes called cancer stem cells (CSC) because they express stem cell markers, and can survive conventional therapies such as chemotherapy, which usually target rapidly replicating tumor cells, and give rise to recurrent tumors that are more chemo-resistant and more aggressive. Thus, it would be desirable to develop a therapy that could selectively target OCIC and be used to complement the conventional therapies. In this study, we isolated a subset of OVCA cells with a CD44 1 phenotype in samples from patients with OVCA that possess CSC properties including the formation of spheroids in culture, self-renewal and the ability to be engrafted in immune-compromised mice. We next explored the use of immunotherapy using fusions of dendritic cells and OCIC to specifically target the OCIC subpopulations. Fusion cells (FCs) prepared in this way activated T cells to express elevated levels of IFN-c with enhanced killing of CD44 1 OVCA cells. We envision a combined approach where conventional therapies such as chemotherapy kill the bulk of tumor cells, whereas OCIC-reactive cytotoxic T lymphocytes target the resistant OCIC fraction. A combined therapy such as this may represent a promising approach for the treatment of OVCA.Epithelial ovarian cancer (EOC) is responsible for the majority of gynecologic cancer deaths despite recent advances in adjuvant chemotherapy. Indeed, the majority of patients with Stage III/IV ovarian cancer (OVCA) that respond initially to standard therapies ultimately relapse due to drug-resistant disease refractory to further treatment with chemotherapy.

show abstract

“…ELISA assisted by the recombinant p53 protein is a simple and reliable method to detect p53 Abs in serum (12). The frequency of serum p53 Abs in ovarian cancer is still controversial in previous reports (13)(14)(15)(16). So it's necessary to analyze p53 Abs in serum from patients with ovarian cancer systematically.…”

Section: Discussionmentioning

confidence: 99%